Chemerin is a novel adipokine associated with obesity and metabolic syndrome.

By K. Bozaoglu, Kristy Bolton, J. McMillan, P. Zimmet, J. Jowett, G. Collier, K. Walder, D. Segal. Endocrinology, 2007

905 citations recorded by the source corpus.

Subfields: Epidemiology, Molecular Biology, Physiology

View Paper: https://www.semanticscholar.org/paper/bcc4070e8325464b6d65e0fb730c31722f7485dc

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. M. Blüher

In Physiology

1. M. Blüher

Citations in the corpus

• Insulin-sensitive obesity. (2010, background): “Increased circulating concentrations of Nampt (35), chemerin (7), progranulin (49), and fetuin-A (37) have been shown to be associated with either insulin resistance, obesity, or both.”
• Metabolic Syndrome and Insulin Resistance: Underlying Causes and Modification by Exercise Training (2013, neutral): “(79,80) found that circulating chemerin levels associate with obesity and the MS in Caucasian and Mexican-American populations.”
• Metabolic Syndrome: Updates on Pathophysiology and Management in 2021 (2022, background): “In humans, several small cohort studies revealed a significant increase in circulating chemerin levels in individuals fulfilling MetS criteria [54–56], and this significance persisted even after adjusting for waist circumference or BMI, since obesity itself is known to increase chemerin levels [57].”